SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Helix Biopharma Files IND for Its Planned Phase II/III Efficacy Trial of Topical Interferon Alpha-2b in Patients With Low-Grade Cervical Lesions